Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.

In vivo BCMA CAR-T therapy achieved a 100% objective response rate with durable remission in one patient for up to 15 months in relapsed/refractory multiple myeloma.

• Why it matters: Long-term safety and efficacy data for in vivo CAR-T therapies are limited, making it essential to evaluate their durability and potential risks in this patient population.
• What they did: Four patients with relapsed/refractory multiple myeloma received in vivo BCMA CAR-T (ESO-T01) without leukapheresis or lymphodepletion, with follow-up up to 15 months, assessing safety, response, and survival.
• The result: One patient maintained a stringent complete response for 15 months, while median progression-free survival was 4.0 months; three patients relapsed or progressed, highlighting the need for further platform optimization.